{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.0","upperLimit":"97.50","value":"0.0"},{"groupId":"OG001","lowerLimit":"0.21","upperLimit":"38.48","value":"8.3"},{"groupId":"OG002","lowerLimit":"0.25","upperLimit":"44.50","value":"10.0"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"1"},{"groupId":"OG001","value":"12"},{"groupId":"OG002","value":"10"}],"units":"Participants"}],"description":"MRD negativity at CR or better assessed by using the IMWG criteria.\n\nPercentage of MRD negative responders at CR along with exact 2- sided 95% were provided by using the Clopper Pearson method.","dispersionType":"95% Confidence Interval","groups":[{"description":"28 day continuous intravenous infusion of AMG 420 200 µg/day followed by a 2 week treatment-free interval, until progressive disease (PD) or relapse as defined by International Myeloma Working Group (IMWG) response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG000","title":"AMG 420 200 µg/Day"},{"description":"28 day continuous intravenous infusion of AMG 420 400 µg/day followed by a 2 week treatment-free interval, until PD or relapse as defined by IMWG response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG001","title":"AMG 420 400 µg/Day"},{"description":"28 day continuous intravenous infusion of AMG 420 600 µg/day followed by a 2 week treatment-free interval, until PD or relapse as defined by IMWG response criteria, unacceptable safety events, next anti-multiple myeloma treatment, or other reason for permanent treatment discontinuation","id":"OG002","title":"AMG 420 600 µg/Day"}],"paramType":"NUMBER","populationDescription":"Safety analysis set includes all participants who enrolled and received at least 1 dose of AMG 420.","reportingStatus":"POSTED","timeFrame":"Up to approximately 3 years","title":"Percentage of Participants With Minimal Residual Disease (MRD) Negativity Response at CR","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}